• A-1210477: Advancing Functional MCL-1 Dependency Analysis in

  2026-06-02

  Discover how MCL-1 inhibitor A-1210477 offers unparalleled specificity for dissecting apoptosis regulation in cancer cells. This article explores deep functional insights—from molecular mechanism to practical protocol optimization—setting a new standard for MCL-1–targeted cancer research.

• FASN Inhibition Sensitizes Pancreatic Cancer to BH3 Mimetics

  2026-06-01

  The referenced study demonstrates that inhibiting fatty acid synthase (FASN) can dramatically sensitize pancreatic ductal adenocarcinoma (PDAC) cells to mitochondrial apoptosis triggered by BH3 mimetic drugs, including ABT-263 (Navitoclax). These findings provide a mechanistic rationale for combining metabolic and apoptotic pathway targeting in the fight against chemoresistant PDAC.

• Sulfisomidine (Sulfamethin): Integrative Evidence for Enzyme

  2026-06-01

  Explore the unique dual role of Sulfisomidine (sulfamethin) as an enzyme kinetics inhibitor and antibacterial tool. This article delivers evidence-driven insights, clinical relevance, and advanced protocol guidance beyond standard applications.

• Nitrocefin: Chromogenic Cephalosporin Substrate for Advanced

  2026-05-31

  Nitrocefin enables rapid, high-sensitivity detection of β-lactamase activity via a robust colorimetric shift, streamlining antibiotic resistance profiling. This guide details optimized workflows, key innovations, and troubleshooting strategies for deploying Nitrocefin in experimental and applied research settings.

• Ruthenium Red: Precision Ca2+ Transport Inhibitor for Cell S

  2026-05-30

  Ruthenium Red enables high-fidelity dissection of calcium-dependent pathways in mechanotransduction, autophagy, and inflammation models. Its dual-site inhibition and robust water solubility position it as the Ca2+ transport inhibitor of choice for reproducible, advanced cell signaling workflows.

• Gamma-linolenic Acid: Applied Workflows for Inflammation Res

  2026-05-29

  Gamma-linolenic acid (GLA) offers a validated, reproducible approach to modeling anti-inflammatory mechanisms and cellular cytotoxicity in vitro. This guide delivers stepwise protocols, troubleshooting strategies, and unique cross-study insights for optimizing GLA-based research across inflammation and metabolic signaling domains.

• Iterative Discovery of TAS2R14 Ligands via FDA-approved Drug

  2026-05-29

  This article reviews the innovation and findings of Fierro et al. (2023), who used a mixed computational and experimental approach to identify new agonists and antagonists for the promiscuous bitter taste receptor TAS2R14. Their iterative method, leveraging an FDA-approved bioactive compound library, revealed extensive ligand diversity and improved virtual screening reliability, with strong implications for drug repositioning and pharmacological target discovery.

• Canonical Anti-Apoptotic Function of MCL-1 in Breast Cancer

  2026-05-28

  This study rigorously demonstrates that breast cancer cell survival depends primarily on the canonical anti-apoptotic function of MCL-1. Genetic deletion or selective inhibition of MCL-1 leads to tumor regression in models, with effects entirely reliant on BAX/BAK-mediated apoptosis, clarifying the mechanistic rationale for targeting MCL-1 in cancer research.

• Technical Workflows for Calpain Inhibitor I, ALLN in Researc

  2026-05-28

  Calpain Inhibitor I, ALLN provides a potent, selective tool for inhibiting calpain and cathepsin proteases in apoptosis, inflammation, and ischemia-reperfusion injury models. It is appropriate for cell-based and animal research settings but should not be used for diagnostic or clinical purposes. Strict attention to solubility, storage, and workflow integration is required for reliable results.

• Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod

  2026-05-27

  This study provides a detailed analysis of the pharmacokinetic variability and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice with diet-induced metabolic dysfunction-associated steatohepatitis (MASH). Its findings inform dosing strategies and highlight how disease-induced changes in metabolism and transporters drive systemic and hepatic exposure.

• Ferroptosis Inducer Erastin Enhances Oncolytic Virus Immunot

  2026-05-27

  The reference study demonstrates that Erastin, a ferroptosis inducer, significantly improves the efficacy of oncolytic vaccinia virus (OVV)-mediated cancer immunotherapy in preclinical models. Erastin acts synergistically with OVV to enhance antitumor immune responses, offering a promising combination strategy for resistant solid tumors.

• T7 RNA Polymerase: Optimizing In Vitro Transcription Workflo

  2026-05-26

  Unlock superior RNA synthesis with T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, renowned for its high specificity and efficiency. This guide delivers actionable workflow enhancements, troubleshooting insights, and practical applications—including RNA vaccine production and advanced RNAi research—grounded in the latest mechanistic science.

• Neurotensin (CAS 39379-15-2): Precision Activator for NTR1 a

  2026-05-26

  Neurotensin is a 13-amino acid neuropeptide acting primarily as a Neurotensin receptor 1 activator. It enables precise studies of GPCR trafficking mechanisms and miRNA regulation, particularly in gastrointestinal and neural systems. APExBIO’s high-purity formulation supports reproducible, interference-minimized workflows.

• Dehydroabietic Acid: Precision Tools for Lipid and Glucose M

  2026-05-25

  Explore how Dehydroabietic acid, a dual PPAR-α/γ agonist, empowers high-fidelity research into lipid metabolism regulation and insulin sensitivity. This article uncovers nuanced applications, protocol insights, and unique mechanistic links to energy metabolism.

• AZD2461: Novel PARP Inhibitor Optimizing Breast Cancer Assay

  2026-05-25

  AZD2461, a next-generation PARP inhibitor, empowers breast cancer research by overcoming Pgp-mediated resistance and enabling robust DNA repair pathway interrogation. This guide details advanced workflows, troubleshooting strategies, and protocol enhancements to maximize reproducibility and cytotoxicity insights in BRCA1-mutated and resistant tumor models.

15693 records 1/1047 page Next 12345 下5页 Last page